Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids (PRIMROSE 1)

What is the purpose of this trial?

Brief Summary:

The primary objective of this study is to demonstrate the superior efficacy versus placebo of OBE2109 alone and in combination with add-back therapy for the reduction of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.


Participation Guidelines

Ages: 18 years and older

Gender: Female only


ObsEva SA

Start Date: 08/29/2018

End Date: 07/31/2019

Last Updated: 11/05/2018

Study HIC#: 2000021141

Get Involved

For more information about this study, contact:
Kristin DeFrancesco
+1 203-785-3852
kristin.defrancesco@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigator

Pinar Kodaman

Principal Investigator